- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Sutro Biopharma (STRO)
Sutro Biopharma stock price live, this page displays NASDAQ STRO stock exchange data. View the STRO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Sutro Biopharma real time stock price chart below.
What Is the Sutro Biopharma Stock Price Today?
The Sutro Biopharma stock price today is 0.900.
What Is the Stock Symbol for Sutro Biopharma?
The stock symbol for Sutro Biopharma is ""STRO.""
What Stock Exchange Does Sutro Biopharma Trade On?
Sutro Biopharma is listed and trades on the NASDAQ stock exchange.
Is Sutro Biopharma a Good Stock to Buy?
Determining whether Sutro Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the STRO quote. (ISIN: US8693671021)
What Is the Sutro Biopharma Stock Price Today?
The Sutro Biopharma stock price today is 0.900.
What Is the Stock Symbol for Sutro Biopharma?
The stock symbol for Sutro Biopharma is ""STRO.""
What Stock Exchange Does Sutro Biopharma Trade On?
Sutro Biopharma is listed and trades on the NASDAQ stock exchange.
Is Sutro Biopharma a Good Stock to Buy?
Determining whether Sutro Biopharma—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the STRO quote. (ISIN: US8693671021)
Fair Value
An estimate of a Sutro Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.829
0.908
52 wk Range
0.523
4.827
STRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
STRO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Sutro Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8290.908
52 wk Range
0.5234.827
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
STRO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Sutro Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
3.114
Upside
+246.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Form 13G Sutro Biopharma For: 13 August
- Investing.com
- Form 13G Sutro Biopharma For: 13 August
- Investing.com
- Sutro Biopharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Sutro Biopharma Company Profile
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma SWOT Analysis
Pipeline Pivot | Sutro Biopharma's strategic shift focuses on preclinical candidates, with STRO-004 leading the charge in antibody-drug conjugate development |
Financial Resilience | Strong cash position of $316.9M provides runway for pipeline advancement, despite restructuring costs and reduced near-term catalysts |
Explore ADC Innovation | Discover Sutro's next-generation dual-payload and immunostimulatory ADCs, potentially revolutionizing cancer treatment approaches |
Market Valuation | Analysts maintain a bullish outlook with a $17 price target, despite recent downgrades, reflecting confidence in Sutro's long-term potential |
Sutro Biopharma Earnings Call Summary for Q4/2024
- Q4 2024: EPS met forecast at -0.83, revenue exceeded at $14.8M; stock plunged 27.51% to $0.906
- Major restructuring announced: focus on 3 ADC programs, workforce reduction, aiming to extend cash runway to Q4 2026
- 2025-2026 expenditures to decrease dramatically; restructuring charges estimated at $40-45M for 2025
- First clinical program STRO4 to start H2 2024; 3 IND submissions planned over next 3 years
- Management exploring partnerships for Livalca; optimistic about ADC platform's potential despite market concerns
Last Updated: 14/03/2025, 17:10
Read Full TranscriptCompare STRO to Peers and Sector
Metrics to compare | STRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTROPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.0x | −0.5x | |
PEG Ratio | 0.01 | −0.08 | 0.00 | |
Price/Book | −2.4x | 1.1x | 2.6x | |
Price / LTM Sales | 0.7x | 8.2x | 3.3x | |
Upside (Analyst Target) | 138.9% | 214.8% | 38.7% | |
Fair Value Upside | Unlock | 27.7% | 5.0% | Unlock |
Analyst Ratings
5 Buy
4 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.114
(+246.03% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.14 / -0.41
Revenue / Forecast
63.74M / 15.79M
People Also Watch
FAQ
What Stock Exchange Does Sutro Biopharma Trade On?
Sutro Biopharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Sutro Biopharma?
The stock symbol for Sutro Biopharma is "STRO."
What Is the Sutro Biopharma Market Cap?
As of today, Sutro Biopharma market cap is 76.30M.
What Is Sutro Biopharma's Earnings Per Share (TTM)?
The Sutro Biopharma EPS (TTM) is -2.51.
When Is the Next Sutro Biopharma Earnings Date?
Sutro Biopharma will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is STRO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Sutro Biopharma Stock Split?
Sutro Biopharma has split 0 times.
How Many Employees Does Sutro Biopharma Have?
Sutro Biopharma has 244 employees.
What is the current trading status of Sutro Biopharma (STRO)?
As of 27 Aug 2025, Sutro Biopharma (STRO) is trading at a price of 0.90, with a previous close of 0.90. The stock has fluctuated within a day range of 0.83 to 0.91, while its 52-week range spans from 0.52 to 4.83.
What Is Sutro Biopharma (STRO) Price Target According to Analysts?
The average 12-month price target for Sutro Biopharma is USD3.11429, with a high estimate of USD7 and a low estimate of USD0.8. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +246.03% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.